Cargando…

CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies

Latency-reversing agents (LRAs), including histone deacetylase inhibitors (HDACi), are being investigated as a strategy to eliminate latency in HIV-infected patients on suppressive antiretroviral therapy. The effectiveness of LRAs in activating latent infection in HIV strains derived from the centra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gray, L R, Cowley, D, Welsh, C, Lu, H K, Brew, B J, Lewin, S R, Wesselingh, S L, Gorry, P R, Churchill, M J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804184/ https://www.ncbi.nlm.nih.gov/pubmed/26303660 http://dx.doi.org/10.1038/mp.2015.111

Ejemplares similares

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
por: Clutton, Genevieve Tyndale, et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
por: Delagrèverie, Héloïse M., et al.
Publicado: (2016)

HIV persistence in the CNS: the final frontier for a cure?
por: Lewin, Sharon R, et al.
Publicado: (2016)

Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus
por: Churchill, Melissa J, et al.
Publicado: (2007)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

HIV cure trial mergers: Spotlighting the epigenetics of latency reversal
por: Denton, Paul W.
Publicado: (2022)

Macrophage Tropism and Cytopathicity of HIV-1 Variants Isolated Sequentially from a Long-Term Survivor Infected with nef-Deleted Virus
por: Gorry, Paul R, et al.
Publicado: (2007)

Impact of latency‐reversing agents on human macrophage physiology
por: Hany, Laurent, et al.
Publicado: (2022)

Latency Reversing Agents: Kick and Kill of HTLV-1?
por: Schnell, Annika P., et al.
Publicado: (2021)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes
por: Gray, Lachlan R., et al.
Publicado: (2013)

Off-Target Effect of Activation of NF-κB by HIV Latency Reversal Agents on Transposable Elements Expression
por: Curty, Gislaine, et al.
Publicado: (2022)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Ex Vivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy
por: Lu, Hao K., et al.
Publicado: (2014)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Diverse effects of interferon alpha on the establishment and reversal of HIV latency
por: Van der Sluis, Renée M., et al.
Publicado: (2020)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo
por: Gorry, Paul R, et al.
Publicado: (2007)

The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells
por: Copertino, Dennis C., et al.
Publicado: (2023)

HIV-1 Entry and Trans-Infection of Astrocytes Involves CD81 Vesicles
por: Gray, Lachlan R., et al.
Publicado: (2014)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
por: Richard, Khumoekae, et al.
Publicado: (2018)

HIV Latency in Myeloid Cells: Challenges for a Cure
por: Chitrakar, Alisha, et al.
Publicado: (2022)

Small Alphaherpesvirus Latency-Associated Promoters Drive Efficient and Long-Term Transgene Expression in the CNS
por: Maturana, Carola J., et al.
Publicado: (2020)

Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source
por: Gray, Lachlan, et al.
Publicado: (2007)

Latency function estimation under the mixture cure model when the cure status is available
por: Safari, Wende Clarence, et al.
Publicado: (2023)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
por: Li, Shifei, et al.
Publicado: (2023)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

l-Arginine as a Bio-Based Curing Agent for Epoxy Resins: Glass Transition Temperature, Rheology and Latency
por: Rothenhäusler, Florian, et al.
Publicado: (2022)

Latency reversal agents affect differently the latent reservoir present in distinct CD4(+) T subpopulations
por: Grau-Expósito, Judith, et al.
Publicado: (2019)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
por: Vignesh, Ramachandran, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ad5632qg0peqk1r24e4lqggkuj